Fig. 3From: Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndromeSensitivity analysis number of work days lost due to dry eye disease showing that at <68 days lost, Cyclosporine A (Restasis) is the less expensive option for treatmentBack to article page